Optimized procedure for renaturation of recombinant human bone morphogenetic protein‐2 at high protein concentration
Authors:
- 20 January 2004
- journal article
- research article
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 85 (6) , 601-609
Abstract
The human gene encoding the mature form of bone morphogenetic protein‐2 (hBMP‐2), a dimeric disulfide‐bonded protein of the cystine knot growth factor family, was expressed in recombinant Escherichia coli using a temperature‐inducible expression system. The recombinant protein was produced in the form of cytoplasmic inclusion bodies and the effect of different variables on the renaturation of rhBMP‐2 was investigated. In particular, variables such as pH, redox conditions, protein concentration, temperature, the presence of different types of aggregation suppressors, and host cell contaminants were studied with respect to their effect on aggregation during refolding and on the final renaturation yield of rhBMP‐2. It is shown that the renaturation yield is particularly sensitive to pH, temperature, protein concentration, and the presence of aggregation suppressors. In contrast, little effect of the redox conditions and the ionic strength on the renaturation yield was observed, as equal yields were obtained in a broad range of reduced to oxidized glutathione ratios and concentrations of NaCl, respectively. The aggregation suppressor 2‐(cyclohexylamino)ethanesulfonic acid (CHES) proved to be superior with respect to the final renaturation yield, although, in comparison to the more common arginine, it was less efficient in preventing aggregation of rhBMP‐2 during refolding. Detergent washing of inclusion bodies was sufficient, as further purification of rhBMP‐2 prior to refolding was without effect on the final renaturation yield. An increase in the concentration of renatured rhBMP‐2 was achieved by a pulsed refolding procedure by which up to a total amount of 2.1 mg mL−1 rhBMP‐2 could be transferred in seven pulses into the renaturation buffer with an overall refolding yield of 38%, corresponding to 0.8 mg mL−1 renatured dimeric rhBMP‐2. Furthermore, a simplified purification procedure is presented that also includes freeze‐drying for long‐term storage of biologically active rhBMP‐2. Finally, it is shown that the appearance of rhBMP‐2 variants could be avoided by using a host strain overexpressing rare codon tRNAs.Keywords
This publication has 31 references indexed in Scilit:
- Systematic Optimization of Expression and Refolding of the Plasmodium falciparum Cysteine Protease Falcipain-2Protein Expression and Purification, 2001
- Continuous refolding of lysozyme with fed-batch addition of denatured protein solutionProcess Biochemistry, 2000
- The Use of rhBMP-2 in Interbody Fusion CagesSpine, 2000
- Crystal structure of human bone morphogenetic protein-2 at 2.7 Å resolution 1 1Edited by R. HuberJournal of Molecular Biology, 1999
- Oxidative Renaturation of Hen Egg-White Lysozyme. Folding vs AggregationBiotechnology Progress, 1998
- Effect of Inclusion Body Contaminants on the Oxidative Renaturation of Hen Egg White LysozymeBiotechnology Progress, 1997
- Bone morphogenetic proteins: multifunctional regulators of vertebrate development.Genes & Development, 1996
- Effective refolding of fully reduced lysozyme with a flow-type reactorProcess Biochemistry, 1996
- Human Bone Morphogenetic Protein 2 Contains a Heparin‐Binding Site which Modifies Its Biological ActivityEuropean Journal of Biochemistry, 1996
- Effects of rare codon clusters on high-level expression of heterologous proteins in Escherichia coliCurrent Opinion in Biotechnology, 1995